Humectant Activity of a New Formulation of Gynomunal® Vaginalgel

Randomized, controlled, crossover clinical study; the subjects will use both formulations with an interval of 1 week (wash out period), in reversed sequence according to the treatment arm assigned at each subject during the basal visit.

Both tested products will be applied in the vagina, using the dedicated applicator, once a day, preferably at bedtime. To investigate the activity of the products under study, 4 visits will be performed: a baseline visit (T0), a visit at the end of the first week-treatment (T1), a visit at the end of the wash out period (T2) and a final visit at the end of the second week-treatment (T3).

Volunteers will be asked to follow their normal life and sexual habits, except for not having sexual intercourse 48 hours prior to each examination.

Inclusion criteria

• Caucasian healthy female subjects,
• complaining vaginal dryness,
• women in menopause since at least 2 years; the starting period of menopause being defined as the date when the last menstruation or metrorragia linked to hormonal unbalance took place,
• women who agree not to start a replacement therapy during the whole duration of the study,
• women who do not present any active cutaneous pathology of external and internal genitalia,
• women who did not receive any drug or cosmetic treatment on their genitalia during the 2 months preceding the trial,
• women who did not apply vaginal products within at least 1 month before the inclusion in the study,
• women who accept to use only the products authorised by the protocol,
• women who accept not to undertake any treatment for internal and external genitalia during the trial,
• women who did not use, phytoestrogenes based products on treated areas less than 4 weeks before inclusion time,
• women accepting to sign the Informed consent form,
• women able to read the material dedicated to volunteers, to abide by the rules of the protocol and ready to accept its constraints

Exclusion criteria

• Volunteers not fulfilling inclusion criteria,
• severe symptoms of vaginal dryness, associated with mucosal signs
• history of intolerance to a vaginal product,
• concomitant participation to another trial,
• refusal to sign the Informed Consent form,
• known allergy to one or several ingredients of the product on trial,
• change in the normal habits in the last 3 months,
• participation in a similar study during the previous 3 months,
• whose insufficient adhesion to the study protocol is foreseeable
• women who start a replacement therapy during the trial
• women who experience during the study the occurrence of any foreseeable risk to use daily the product on trial.